Top Executive Cashes In on TransMedics Stock

Tip Ranks
2025.11.27 02:12
portai
I'm PortAI, I can summarize articles.

Anil P. Ranganath, a top executive at TransMedics Group, sold 3,000 shares valued at $435,660. TMDX stock rose 10.4% to $129.19 due to strong Q3 financial results, with 32.2% revenue growth. Analysts adjusted price targets; Piper Sandler lowered its target, while Canaccord raised it. Spark rates TMDX as Outperform, citing strong financials and bullish momentum, though caution is advised due to high P/E ratio.

New insider activity at TransMedics Group ( (TMDX) ) has taken place on November 26, 2025.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Anil P. Ranganath, the Senior Vice President, General Counsel, and Secretary of TransMedics Group, recently sold 3,000 shares of the company’s stock. This transaction was valued at $435,660.

Recent Updates on TMDX stock

TransMedics Group’s stock saw a notable increase of 10.4% to $129.19, driven by strong Q3 2025 financial results and strategic initiatives. The company reported a 32.2% year-over-year revenue growth, reaching approximately $144 million, with significant contributions from its U.S. transplant revenue. Despite a seasonal slowdown and sequential revenue decline, the company improved its operating margins and strengthened its cash position. Analysts adjusted their price targets based on these developments: Piper Sandler lowered its target due to revenue landing slightly below consensus, despite a strong bottom-line performance and raised full-year guidance, while Canaccord raised its target, viewing the current stock price as a buying opportunity given the company’s robust performance and strategic expansion plans. Overall, the positive outlook and strategic initiatives, including international expansion and collaborations, suggest a promising trajectory for TransMedics.

Spark’s Take on TMDX Stock

According to Spark, TipRanks’ AI Analyst, TMDX is a Outperform.

TransMedics Group’s strong financial performance and positive technical indicators are the most significant factors driving the stock score. The company’s robust revenue growth, improved profitability, and cash flow generation underscore its financial health. Technical analysis shows bullish momentum, though caution is advised due to potential overbought conditions. Valuation remains a concern with a high P/E ratio, and the earnings call provided a balanced outlook with more positive highlights than challenges.

To see Spark’s full report on TMDX stock, click here.

More about TransMedics Group

YTD Price Performance: 119.55%

Average Trading Volume: 982,443

Technical Sentiment Signal: Buy

Current Market Cap: $4.99B

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer